GlassScriptPhysician profile
Nathan E Hartgrove
NPI 1538420229
$4,400.55
in general payments reported to CMS, 2019-2025
33 companies · $33.16 in 2025
The $33.16 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,476 · 2020: $1,030 · 2021: $1,736 · 2022: $70.87 · 2023: $30.52 · 2024: $23.48 · 2025: $33.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $87.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $87.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $534.95 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $476.01 | 2019-2021 | |
| Amgen INC. | $307.03 | 2019-2021 | |
| Abbvie INC. | $260.77 | 2021-2024 | |
| Pfizer INC. | $255.52 | 2019-2021 | |
| Astellas Pharma US INC | $234.00 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $208.59 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $191.43 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $176.59 | 2020-2021 | |
| Amarin Pharma, INC. | $174.95 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $168.13 | 2019-2023 | |
| Arbor Pharmaceuticals, INC. | $161.32 | 2019-2021 | |
| Esperion Therapeutics, INC. | $138.87 | 2020-2021 | |
| Eisai INC. | $133.56 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $122.65 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.61 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.65 | 2019-2021 | |
| Allergan, INC. | $90.97 | 2019-2020 | |
| Glaxosmithkline, LLC. | $86.68 | 2019-2021 | |
| Lilly USA, LLC | $74.76 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $59.87 | 2019-2021 | |
| Gilead Sciences, INC. | $59.33 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.01 | 2019-2021 | |
| Horizon Therapeutics Plc | $47.54 | 2019-2020 | |
| Abbott Laboratories | $41.22 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $28.93 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $15.92 | 2019 | |
| Mylan Specialty L.P. | $14.30 | 2021 | |
| Sunovion Pharmaceuticals INC. | $13.86 | 2021 | |
| Medtronic Vascular, INC. | $12.38 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $12.15 | 2021 | |
| Boston Scientific Corporation | $11.10 | 2019 | |
| Clarus Therapeutics INC. | $9.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Hartgrove listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.